Autoimmunity associated with chemically induced thymic dysplasia

Daisuke Nagakubo1,2, Jeremy B. Swann1, Stefanie Birmelin1 and Thomas Boehm1

1 Department of Developmental Immunology, Max Planck Institute of Immunobiology and Epigenetics, Stuebeweg 51, D-79108 Freiburg, Germany
2 Present address: Department of Fundamental Biosciences, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan

Correspondence to: T. Boehm; E-mail: boehm@immunbio.mpg.de

Received 7 August 2017, editorial decision 29 August 2017; accepted 11 September 2017

Abstract

Autoimmune and inflammatory conditions are frequent complications in patients with reduced numbers of T cells. Here, we describe a mouse model of thymic stromal dysplasia resulting in peripheral T-cell lymphopenia. In Foxn1:CFP-NTR transgenic mice, the bacterial nitroreductase enzyme is expressed in thymic epithelial cells and converts the prodrug CB1954 into a cytotoxic agent. This strategy enables titratable and durable destruction of thymopoietic tissue in early embryogenesis. Our results indicate that the resulting low levels of thymic capacity for T-cell production create a predisposition for the development of a complex autoimmune syndrome, chiefly characterized by inflammatory bowel disease and lymphocytic organ infiltrations. We conclude that the Foxn1:CFP-NTR transgenic mouse strain represents a suitable animal model to optimize established clinical protocols, such as thymus transplantation, to correct various forms of thymic dysplasia and to explore novel treatment options.

Keywords: animal model, conditional cell ablation, Foxn1, inflammatory bowel disease, thymus

Introduction

In a recent retrospective analysis, autoimmune and inflammatory complications were noted in approximately a quarter of patients with primary immunodeficiency syndromes, particularly notable in situations of T lymphopenia (1). Interestingly, in a select group of patients, the phenotype of normal immunoglobulin levels with reduced or absent cellular immune reactivity was attributed to thymic dysplasia (2-6). A large fraction of such patients suffers from DiGeorge syndrome, first described as a cause of immunodeficiency about 50 years ago (7, 8); indeed, numerous reports have demonstrated a high prevalence of autoimmunity in these patients (1, 9-11). Based on the autoimmune phenotypes of other types of primary immunodeficiencies (1), it is tempting to speculate that the size of the residual thymic mass in the genetically heterogeneous group of thymic dysplasia patients determines whether or not autoimmunity develops. Considering the fact that rodents without thymopoietic activity lack autoimmunity (12), the presence of residual thymic masses of intermediate size might predispose patients to the development of autoimmunity as a result of immune dysregulation.

Here, we describe a mouse model that is based on a conditional cell ablation strategy to reduce the number of thymic epithelial cells (TECs) during embryogenesis, resulting in varying degrees of thymic hypoplasia. In our first report on this strategy, we concerned ourselves with the developmental distinction between thoracic and cervical thymus tissue (13). Here, we focus on the long-term immunological consequences of prenatally induced thymus hypoplasia/aplasia. Our results demonstrate that an intermediate level of residual thymopoiesis indeed predisposes mice to the development of autoimmunity, establishing a suitable animal model for the immunological perturbations resulting from similar immunodeficient states in patients.

Methods

Mice

Foxn1lacZ (14), Foxn1:CFP-NTR (13) and Foxn1:eGFP (15) transgenic mice were described earlier and kept in the animal facility of the Max Planck Institute of Immunobiology and Epigenetics under specific pathogen-free conditions. All animal experiments were performed in accordance with relevant guidelines and regulations, approved by the review committee of the Max Planck Institute of Immunobiology and Epigenetics and the Regierungspräsidium Freiburg, Germany (licence Az 35-9185.81/G-12/85).
Chemically induced thymic dysplasia

Treatment with CB1954

Treatment of mice with CB1954 was done according to Corbeaux et al. (13). Pregnant mice were injected intra-peritoneally on 3 consecutive days (E12.5, E13.5, E14.5 of gestation).

Tissue transplantation

Cervical thymi and thoracic thymus tissue were obtained from adult Foxn1:eGFP mice (15), as this facilitates the detection of the small cervical thymic lobes. In this strain (of mixed C57BL/6; FVB background), the frequency of cervical thymi is in the order of 75%, with an average of 1.25 cervical lobes per animal (range 1–3 lobes). Tissue fragments were transplanted under the kidney capsule of adult Foxn1−/− mice using a technique essentially equivalent to that described in Taguchi et al. (16).

Histology

Paraffin-embedded tissue sections were stained with haematoxylin/eosin according to standard techniques. Colitis score was determined following the procedure described in Izcue et al. (17).

Flow cytometry

Procedures for the analysis of haematopoietic cells in thymus, spleen and lymph nodes have been described in Swann et al. (18); see Supplementary Table 1, available at International Immunology Online, for list of antibodies.

Statistical analysis

T-tests (two-tailed) were used to determine the significance levels of the differences between the means of two independent samples, considering equal or unequal variances as determined by the F-test. For multiple tests, the conservative Bonferroni correction was applied.

Results and discussion

Near-total ablation of the thymic epithelium during embryogenesis

Our aim was to establish an animal model for the immunological consequences of thymic dysplasia. To this end, we employed a transgenic mouse model in which the bacterial nitroreductase gene (NTR) is expressed in TECs under the control of the mouse Foxn1 promoter (13). During embryonic development, the large majority of TECs express Foxn1 and thus also the bacterial enzyme from the transgenic expression cassette. NTR converts the CB1954 prodrug into a cytotoxic alkylating agent (19), thereby selectively killing expressing cells. To avoid the deleterious effects of CB1954 on pregnant mothers, crosses were used in which only the father was transgenic for the Foxn1:CFP-NTR transgene; note that NTR is expressed as a fusion protein with CFP to visualize expression of the transgene. When pregnant mothers (carrying both transgenic and non-transgenic embryos) are treated with CB1954 at the end of the second trimester, near-total ablation of the thoracic thymus can be achieved, as illustrated by the loss of CFP fluorescence (Fig. 1A). The timing of CB1954 treatment ensures that any cervical thymic tissue which develops at later stages of intrauterine development is unaffected by this treatment (13). Since not all individuals of our transgenic strain possess cervical thymi (15), our strategy was expected to result in cohorts of mice with variable thymic masses, ranging from no thymopoietic remnant (mice with total ablation of thoracic thymus and without cervical thymi) at one end of the spectrum, to mice with small pockets of thoracic thymus (Fig. 1B) and cervical thymic tissue at the other. The non-transgenic littermates served as controls for possible confounding effects resulting from the handling of pregnant mice. In conclusion, our strategy enables us to examine the consequences of variable degrees of thymic developmental dysplasia.

Phenotypic consequences of chemically induced thymic dysplasia

When we followed a large cohort of CB1954-treated non-transgenic and transgenic mice, we noticed that, beginning at 2–3 months of age, a progressively larger fraction of mice exhibited weight loss and diarrhoea (Fig. 1C), often associated with enlarged lymph nodes and splenomegaly (Fig. 1D). Inflammatory bowel disease was invariably associated with diarrhoea (Fig. 1E), as are lymphocytic infiltrations in the gut (Fig. 1F and G) and in other organs, such as liver, pancreas and salivary gland (Fig. 1H). All animals affected by this complex autoimmune syndrome were transgenic; no autoimmune phenotype was observed in the non-transgenic (control) littermates despite their being exposed to the CB1954 produg during intrauterine development. Increased titres of auto-antibodies were not detectable (data not shown).

The cohorts of mice described above were additionally examined for the degrees of thymopoietic activity by determining the number of CD4/CD8 double-positive thymocytes in the neck region and the thoracic cavity. The identification of small remnants of thymic epithelium was aided by the fluorescence emanating from the CFP-NTR fusion protein expressed in stromal cells (see Fig. 1A); however, because the CFP fluorescence signal is weak, it was not always possible to unambiguously identify all thymopoietic tissues in the mediastinum and, in particular, the neck regions. For the analysis of thymopoietic activity, we therefore removed large parts of the anterior upper mediastinal and neck tissues in order to comprehensively survey all sites of potential thymopoietic activity. As a consequence, this strategy necessitated that we focus on cells with the surface phenotype of CD4/CD8 double-positive thymocytes, to avoid confounding effects by co-sampling of non-thymic (i.e. lymph node) tissues. Overtly sick mice were euthanized at various ages; by the age of 35 weeks, most affected mice had developed diarrhoea, although the condition of some initially healthy mice deteriorated at later time points (Fig. 1C). Irrespective of the time point of analysis, we recovered fewer CD4/CD8 double-positive thymocytes (about 2–3 orders of magnitude) from the thoracic and neck regions in transgenic mice exposed to CB1954 than from control littermates, indicating the presence of persistent thymic hypoplasia (Fig. 2A).
Peripheral lymphopenia correlates with thymopoietic activity

Compared to control mice, all transgenic mice exhibited peripheral T-cell lymphopenia (Fig. 2B), with a prominent phenotypic signature of activation indicative of homeostatic proliferation (Fig. 2C). Interestingly, healthy transgenic mice did not have higher numbers of T cells in the periphery than sick transgenic mice (Fig. 2B), indicating that the overall number of peripheral T cells is a poor predictor of outcome. By contrast, the fraction of peripheral T cells expressing CD44 (CD3\(^+\)CD44\(^+\)CD25\(^-\)) correlates with the presence of diarrhoea (Fig. 2C). Since the expression of CD44 is an indicator of homeostatic proliferation (20), it appears that the peripheral T-cell compartment in mice eventually developing autoimmunity was initially smaller than that of mice maintaining immune homeostasis. Hence, homeostatic proliferation of
Peripheral T cells predisposes to autoimmunity, a well-known clinical phenomenon (1). Indeed, when compared to an autoimmunity-stricken sibling, transgenic mice without diarrhoea exhibit a larger fraction of naive CD3+CD62L+CD44− splenic T cells, and a smaller fraction of activated CD62L−CD44+ T cells (Supplementary Figure 1, available at International Immunology Online). In addition, in transgenic mice with autoimmunity, we observed low numbers of splenic T cells with a regulatory phenotype (CD3+CD4+CD44–CD25+), whereas apparently healthy transgenic mice had two to three times

**Fig. 2.** Peripheral lymphopenia as a consequence of thymic dysplasia. (A) Number of CD4/CD8 double-positive thymocytes in combined mediastinal and cervical tissues. Mice are grouped according to age, genotype and clinical condition (absence/presence of diarrhoea); note that wild-type mice never developed diarrhoea. Since there is a constant albeit age-dependent relationship between the number of thymocytes and the number of TECs (26, 27), it is possible to estimate the fraction of thymopoietic tissue remaining in the transgenic mice. Because sick mice tend to have lower numbers of CD4/CD8 double-positive thymocytes, we calculated the fraction of thymopoietic tissue only for the apparently healthy cohorts of transgenic mice. The thymopoietic capacity of the younger group of mice (11–39 weeks of age) amounts to ~0.1% of control mice, and the thymopoietic capacity of the cohort of older mice corresponds to ~1% of controls. Note that in one of the four transgenic mice of the 11–39-week-old cohort of apparently healthy mice, no CD4+/CD8+ double-positive thymocytes could be found; this data point cannot be displayed in the logarithmic representation of the results chosen for this panel. (B) Number of CD3+ T cells in the spleen. (C) Percentage of splenic CD3+ T cells expressing CD44. (D) Absolute numbers of T cells with regulatory phenotype (CD3+CD4+CD44–CD25+). (E) Proportion of CD44–CD25+ cells among CD3+CD4+ splenocytes. P values exceeding 0.20 are categorized as not significant (ns).
more of such cells (Fig. 2D). This difference was also seen when we compared the fractions of CD44 CD25+ cells among CD4+ splenic T cells (Fig. 2E). Collectively, these findings support the notion that a state of immune dysregulation underlies the autoimmune phenomena observed in our model.

Cervical thymi are not solely responsible for the autoimmunity phenotype

In its present form, our transgenic model is tailored to specifically destroy the thoracic but not the cervical thyroid tissues (13). Therefore, it was important to rule out the possibility that the observed autoimmunity was caused by abnormal T-cell differentiation and/or selection in the residual cervical thymi per se in (at least) some treated transgenic animals (13). To address this issue, we transplanted cervical thymi and/or fragments of thoracic thymi under the kidney capsule of Foxn1-deficient nude mice. Since nude mice entirely lack thymopoietic activity, they are protected from any T-lymphopenia-associated autoimmunity (21); hence, any autoimmunity arising after transplantation must be caused, directly or indirectly, by the grafted tissues. A total of eight nude mice received transplants of thoracic or cervical thymi, four of which developed an autoimmune syndrome, chiefly characterized by diarrhoea and/or splenomegaly, mirroring the frequency of autoimmunity in mice with dysplastic thymus (Fig. 1C); sick mice were euthanized between 7 and 13 weeks after transplantation, whereas the apparently healthy mice were monitored for up to 37 weeks after transplantation (Supplementary Table 2, available at International Immunology Online). The number of peripheral T cells varied; although no correlation existed between peripheral T cell numbers and clinical outcome; hence, as observed after chemically induced thymic aplasia (Fig. 2B), a low cell count was not predictive of diarrhoea (Fig. 2B). Hence, we conclude that in our system, and in accordance with previous results (22), T cells produced by cervical thymi per se are not associated with autoimmunity (Supplementary Table 2, available at International Immunology Online). Therefore, rather than being caused by a qualitatively different population of T cells maturing within cervical thymus, the autoimmune phenomena observed in our model can be attributed to the chronic lymphopenic state of and the ensuing imbalance in immunoregulatory mechanisms in these mice.

Conclusion

Collectively, our present results indicate that Foxn1:CFP-NTR transgenic mice represent a useful model of thymic dysplasia. As shown previously, the degree of TEC ablation can be adjusted by modifications of the intensity of the pharmacological treatment during pregnancy (13). We anticipate that this transgenic system will find its chief use in modelling congenital thymic dysplasia and in exploring and optimizing suitable treatment options, such as thymus transplantation (23). Future technical modifications might render this model applicable in the examination of the effect of postnatal insults (infectious or iatrogenic) to the thymic epithelial compartment. At present, one of the major obstacles for this type of application is the activity of the Foxn1 promoter also in the suprabasal keratinocyte layer of skin (24); treatment of mice with the prodrug after the onset of Foxn1 expression in keratinocytes (after E.14.5) causes severe damage to the skin, with only few embryos surviving this treatment. Hence, efforts are underway to modify the 28 kb promoter (25) currently used in the expression cassette to render it specific for the thymic epithelium, in order to be able to induce thymic dysplasia during late gestation and after birth.

Supplementary data

Supplementary data are available at International Immunology Online.

Funding

This work was supported by the Max Planck Society, the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013) ERC grant agreement no. 323126 and the Deutsche Forschungsgemeinschaft (SFB1160, P16).

Acknowledgement

We thank A. Izcue for help with histological assessment of colon specimens.

Conflicts of interest statement: The authors declared no conflicts of interest.

References

1 Fischer, A., Provot, J., Jais, J. P., Alcais, A., Maclaouii, N. and Members of the CEREDIH French PID Study Group. 2017. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2016.12.978.
2 Nezelof, C., Jammet, M. L., Lortholary, P., Labrune, B. and Lamy, M. 1964. Hereditary thymic hypoplasia: its place and responsibility in a case of lymphocytic, normoplasmiocytic and normoglobulinemic aplasia in an infant. Arch. Fr. Pediatr. 21:897.
3 Rezza, E., Aiuti, F., Businco, L. and Castello, M. A. 1974. Familial lymphopenia with T lymphocyte defect. J. Pediatr. 84:178.
4 Fireman, P., Johnson, H. A. and Gitlin, D. 1966. Presence of plasma cells and gamma-1-M-globulin synthesis in a patient with thymic alymphoplasia. Pediatrics 37:485.
5 Fulginiti, V. A., Hathaway, W. E., Pearlman, D. S. et al. 1966. Dissociation of delayed-hypersensitivity and antibody-synthesis capacities in man. Report of two sibships with thymic dysplasia, lymphoid tissue depletion, and normal immunoglobulins. Lancet 2:5.
6 Allibone, E. C., Goldie, W. and Marmion, B. P. 1964. Pneumocystis carinii pneumonia and progressive vaccinia in siblings. Arch. Dis. Child. 39:26.
7 Strong, W. B. 1968. Familial syndrome of right-sided aortic arch, mental deficiency, and facial dysmorphism. J. Pediatr. 73:882.
8 DiGeorge, A. M. 1968. Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism. Birth Defects Orig. Art. Ser. 4:116.
9 McLean-Tooke, A., Spickett, G. P. and Gennery, A. R. 2007. Immunodeficiency and autoimmunity in 22q11.2 deletion syndrome. Scand. J. Immunol. 66:1.
10 Zemble, R., Luning Prak, E., McDonald, K., McDonald-McGinn, D., Zackai, E. and Sullivan, K. 2010. Secondary immunologic consequences in chromosomes 22q11.2 deletion syndrome. (DiGeorge syndrome/velocardiofacial syndrome). Clin. Immunol. 136:409.
11 Brown, J. J., Datta, V., Browning, M. J. and Swift, P. G. 2004. Graves’ disease in DiGeorge syndrome: patient report with a
review of endocrine autoimmunity associated with 22q11.2 deletion. *J. Pediatr. Endocrinol. Metab.* 17:1575.

12 Taguchi, O. and Nishizuka, Y. 1987. Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. *J. Exp. Med.* 165:146.

13 Corbeaux, T., Hess, I., Swann, J. B., Kanzler, B., Haas-Assenbaum, A. and Boehm, T. 2010. Thymopoiesis in mice depends on a Foxn1-positive thymic epithelial cell lineage. *Proc. Natl Acad. Sci. USA* 107:16613.

14 Nehls, M., Kyewaki, B., Messerle, M. *et al.* 1996. Two genetically separable steps in the differentiation of thymic epithelium. *Science* 272:886.

15 Terszowski, G., Müller, S. M., Bleul, C. C. *et al.* 2006. Evidence for a functional second thymus in mice. *Science* 312:284.

16 Taguchi, O., Takahashi, T., Seto, M., Namikawa, R., Matsuyama, M. and Nishizuka, Y. 1986. Development of multiple organ-localized autoimmune diseases in nude mice after reconstitution of T cell function by rat fetal thymus graft. *J. Exp. Med.* 164:60.

17 Izcue, A., Hue, S., Buonocore, S. *et al.* 2008. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. *Immunity* 29:559.

18 Swann, J. B., Weyn, A., Nagakubo, D. *et al.* 2014. Conversion of the thymus into a bipotent lymphoid organ by replacement of FOXN1 with its paralog, FOXN4. *Cell Rep.* 8:1184.

19 Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P. and Collins, M. K. 1995. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. *Eur. J. Cancer* 31A:2362.

20 Fortner, K. A., Bond, J. P., Austin, J. W., Boss, J. M. and Budd, R. C. 2017. The molecular signature of murine T cell homeostatic proliferation reveals both inflammatory and immune inhibition patterns. *J. Autoimmun.* 82:47.

21 Sakaguchi, S. and Sakaguchi, N. 1988. Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A-treated mice causes organ-specific autoimmune disease in athymic nude mice. *J. Exp. Med.* 167:1479.

22 Smolarchuk, C., Zhu, L. F., Chan, W. F. and Anderson, C. C. 2014. T cells generated in the absence of a thoracic thymus fail to establish homeostasis. *Eur. J. Immunol.* 44:2263.

23 Davies, E. G., Cheung, M., Gilmour, K. *et al.* 2017. Thymus transplantation for complete DiGeorge syndrome: European experience. *J. Allergy Clin. Immunol.* doi: 10.1016/j.jaci.2017.03.020.

24 Lee, D., Prowse, D. M. and Brissette, J. L. 1999. Association between mouse nude gene expression and the initiation of epithelial terminal differentiation. *Dev. Biol.* 208:362.

25 Bleul, C. C. and Boehm, T. 2005. BMP signaling is required for normal thymus development. *J. Immunol.* 175:5213.

26 Gray, D. H., Seach, N., Ueno, T. *et al.* 2006. Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. *Blood* 108:3777.

27 Nagakubo, D., Krauth, B. and Boehm, T. 2017. Genetic and non-genetic determinants of thymic epithelial cell number and function. *Sci. Rep.* 7:10314. doi:10.1038/s41598-017-10746-8.